معرفی
Jukka Alinikula is an Adjunct Professor at the University of Turku's Institute of Biomedicine, specifically within the Unit of Infection and Immunity. He also serves as a University Lecturer in immunology and drug development, and as the Education Director of the Immudocs program. His research focuses on somatic hypermutation mechanisms in B lymphocytes, exploring how antibody diversity is generated while avoiding oncogenic mutations. Alinikula completed his PhD at the University of Turku (Lassila Lab), followed by a postdoc at Yale University (Schatz Lab).
Research Interests: Alinikula’s work investigates the targeting of somatic hypermutation to immunoglobulin genes versus proto-oncogenes. His lab uses modern techniques like reporter assays, CRISPR-based screens, and single-cell transcriptomics to dissect mutation enhancer functions. Key topics include genome stability, lymphoma etiology, and the interplay between antibody diversification and cancer risk.
Teaching: He teaches immunology and immunopharmacology across bachelor’s, master’s, medical, and doctoral programs, emphasizing case-based learning and practical laboratory training. Supervised students include PhD candidates in immunology and drug development.
Labs/Teams: Leads his own research group at the Institute of Biomedicine, collaborating extensively with international teams (e.g., Yale, Czech Academy of Sciences). Active in the InFLAMES Flagship initiative for immune system research.
